Non-Traumatic Subdural Hematoma and Cancer: A Cohort Study

Figures & data

Table 1 Absolute Risks and Standardized Incidence Ratios of Site-Specific Cancers During the First Year of Follow-Up Among Patients with Non-Traumatic Subdural Hematoma, Denmark, 1996–2019. Only Sites with Five or More Recorded Cancer Cases are Presented

	Observed (n)	Expected (n)	Risk % (95% CI)	SIR (95% CI)
Overall	77	45.3	2.8 (2.2–3.5)	1.7 (1.3–2.1)
Lungs, bronchi, and trachea	7	4.5	0.3 (0.1–0.5)	1.6 (0.6–3.2)
Prostate	5	6.2	0.2 (0.1–0.4)	0.8 (0.3–1.9)
Membranes of the brain and spinal meninx	7	0.3	0.3 (0.1–0.5)	25.8 (10.4–53.2)
Non-Hodgkin malignant lymphoma	7	1.5	0.3 (0.1–0.5)	4.7 (1.9–9.8)
Myeloid leukemia	5	0.3	0.2 (0.1–0.4)	16.3 (5.3–37.9)
Basal cell skin carcinoma	11	9.7	0.4 (0.2–0.7)	1.1 (0.6–2.0)
Other skin cancers (excluding basal cell skin carcinoma)	5	2.6	0.2 (0.1–0.4)	1.9 (0.6–4.4)
All other cancers	30	20.3	1.1 (0.8–1.6)	1.5 (1.0–2.1)

Abbreviations: CI, confidence interval; SIR, standardized incidence ratio.

Table 2 Absolute Risks and Standardized Incidence Ratios of Site-Specific Cancers During Subsequent Years of Follow-Up Among Patients with Non-Traumatic Subdural Hematoma, Denmark, 1996–2019. Only Sites with Five or More Recorded Cancer Cases are Presented. The Median Follow-Up Time Was 3.6 Years (Interquartile Range: 0.2–8.6 Years)

	Observed (n)	Expected (n)	Risk % (95% CI)	SIR (95% CI)
Overall	272	283.9	27.8 (19.1–37.2)	1.0 (0.9–1.1)
Colorectal	29	30.1	2.3 (1.4–3.5)	1.0 (0.6–1.4)
Liver	6	2.6	0.5 (0.2–1.0)	2.3 (0.9–5.0)
Pancreas	7	5.9	0.5 (0.2–1.0)	1.2 (0.5–2.4)
Lungs, bronchi, and trachea	29	26.6	6.3 (1.1–18.5)	1.1 (0.7–1.6)
Malignant melanoma	8	7.6	0.6 (0.3–1.1)	1.0 (0.5–2.1)
Other skin cancers (excluding basal cell skin carcinoma)	16	18.3	1.8 (0.7–3.6)	0.9 (0.5–1.4)
Basal cell skin carcinoma	57	64.9	4.6 (2.9–6.8)	0.9 (0.7–1.1)
Breast	13	16.0	1.4 (0.6–2.6)	0.8 (0.4–1.4)
Prostate	32	36.9	2.4 (1.6–3.4)	0.9 (0.6–1.2)
Urinary bladder	11	15.3	0.8 (0.4–1.4)	0.7 (0.4–1.3)
Brain	7	3.6	0.5 (0.2–1.0)	1.9 (0.8–4.0)
Non-Hodgkin malignant lymphoma	12	9.6	1.1 (0.5–2.0)	1.3 (0.7–2.2)
Lymphoid leukemia	6	3.3	0.4 (0.2–0.8)	1.8 (0.7–4.0)
Metastases and non-specified cancer in lymph nodes	10	4.5	1.9 (0.5–5.1)	2.2 (1.1–4.1)
All other cancers	29	38.7	3.0 (1.8–4.6)	0.7 (0.5–1.1)

Abbreviations: CI, confidence interval; SIR, standardized incidence ratio.